Homology Medicines, Inc.

NasdaqGS:FIXX Stock Report

Mkt Cap: US$87.9m

Homology Medicines Future Growth

How is Homology Medicines forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-14.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqGS:FIXX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202523-135-70-965
12/31/20245-140-124-1306
12/31/20234-124-113-1108
9/30/20223-4-119-117N/A
6/30/20224-1-119-117N/A
3/31/20225-3-113-111N/A
12/31/202134-96-112-110N/A
9/30/202134-92-94-91N/A
6/30/202133-90-97-94N/A
3/31/202131-94-101-98N/A
12/31/20203-129-98-94N/A
9/30/20202-123-116-109N/A
6/30/20202-124-114-106N/A
3/31/20202-115-113-99N/A
12/31/20192-104-113-91N/A
9/30/20192-99-107-73N/A
6/30/20193-83-98-61N/A
3/31/20194-69-84-49N/A
12/31/20185-56-68-43N/A
9/30/20184-49-22-12N/A
6/30/20183-41-9-4N/A
3/31/20181-35-20N/A
12/31/2017N/A-3056N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: FIXX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: FIXX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: FIXX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: FIXX's revenue (64.8% per year) is forecast to grow faster than the US market (6.9% per year).

High Growth Revenue: FIXX's revenue (64.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: FIXX is forecast to be unprofitable in 3 years.


Discover growth companies